Clear Street Group Inc. Invests $87.37 Million in Hims & Hers Health, Inc. $HIMS

Key Points

• Clear Street Group Inc. bought 1,540,401 shares of Hims & Hers in Q3 (about 0.68% ownership), a stake valued at approximately $87.37 million and the firm's 18th largest position.
• A settlement and commercial agreement with Novo Nordisk spurred analyst upgrades and sharp rallies, but ongoing regulatory scrutiny of compounded GLP‑1s, margin pressures and recent volatility keep the outlook mixed.
• Hims & Hers posted $0.08 EPS (beating estimates), revenue up 28.4% year‑over‑year, and authorized a $250 million share repurchase program (roughly 3% of shares outstanding).

Clear Street Group Inc. acquired a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,540,401 shares of the company's stock, valued at approximately $87,372,000. Hims & Hers Health comprises 0.3% of Clear Street Group Inc.'s holdings, making the stock its 18th largest position. Clear Street Group Inc. owned approximately 0.68% of Hims & Hers Health as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in the stock. Virtus Advisers LLC bought a new position in Hims & Hers Health during the second quarter valued at about $26,000. Quent Capital LLC bought a new stake in shares of Hims & Hers Health in the 3rd quarter worth approximately $28,000. Binnacle Investments Inc bought a new stake in shares of Hims & Hers Health in the 3rd quarter worth approximately $28,000. Geneos Wealth Management Inc. acquired a new stake in shares of Hims & Hers Health during the 1st quarter worth approximately $30,000. Finally, Hilltop National Bank bought a new stake in shares of Hims & Hers Health during the third quarter valued at approximately $35,000. Institutional investors own 63.52% of the company's stock.

Insiders Place Their Bets

In related news, insider Irene Becklund sold 8,411 shares of Hims & Hers Health stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $308,767.81. Following the completion of the transaction, the insider directly owned 2,126 shares of the company's stock, valued at $78,045.46. This trade represents a 79.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Patrick Harrison Carroll sold 10,021 shares of the business's stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $367,870.91. Following the completion of the transaction, the insider owned 169,940 shares in the company, valued at approximately $6,238,497.40. This trade represents a 5.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 80,463 shares of company stock worth $2,846,696 in the last quarter. 13.71% of the stock is owned by corporate insiders.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Novo Nordisk pact ends lawsuit and establishes a commercial pathway for Ozempic and Wegovy on Hims’ platform — the agreement removes a major legal overhang and directly boosts revenue and credibility expectations. Hims shares notch record week as Novo pact spurs optimism
• Positive Sentiment: Several broker notes and price‑target/upside forecasts have followed the Novo news, including bullish coverage that highlights strong upside potential and helped drive volume. Barclays Forecasts Strong Price Appreciation for Hims & Hers Health NYSE: HIMS Stock
• Positive Sentiment: Pre‑market and intraday rallies (big volume spikes) reflected momentum traders buying the Novo settlement and analyst upgrades. Hims & Hers Health shares rally continues, up 7% in premarket Thursday
• Neutral Sentiment: Bank of America moved its coverage (raised to Neutral), and other firms are re‑rating the stock; analyst interest increases liquidity but opinions differ on valuation and risks. Hims & Hers Health NYSE: HIMS Raised to Neutral at Bank of America
• Neutral Sentiment: Corporate hires (communications leader) and company messaging improvements aim to steady the narrative as the Novo story evolves — helps investor relations but not an immediate earnings driver. Hims & Hers Adds Communications Leader As Expansion And Novo Story Evolve
• Negative Sentiment: Regulatory and margin pressures remain a material risk: FDA crackdown on compounded GLP‑1 formulations, prior warning letters and potential enforcement actions have pressured sentiment and valuation. Is Hims & Hers Really the Growth Stock to Buy That It Appears?
• Negative Sentiment: Shares have been down sharply over recent months and saw volatility around company headlines; some outlets flagged a ~29% three‑month decline and one‑day drops that reflect lingering execution and margin concerns. Hims & Hers Plunges 29.4% in Three Months: How to Play the Stock?
• Negative Sentiment: Short‑term pullbacks (including a recent ~7.9% one‑day drop) show that headline risk still drives outsized moves; investors should weigh upside from the Novo deal against execution, regulatory and margin risks. Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $24.74 on Friday. The business has a 50 day simple moving average of $23.84 and a 200 day simple moving average of $37.38. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. The company has a market capitalization of $5.64 billion, a PE ratio of 48.51, a price-to-earnings-growth ratio of 2.34 and a beta of 2.55. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $70.43.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.06. The firm had revenue of $617.82 million for the quarter, compared to analysts' expectations of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The business's revenue was up 28.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.11 earnings per share. On average, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health declared that its board has initiated a share repurchase plan on Monday, November 17th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the company to reacquire up to 3% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on HIMS shares. Weiss Ratings restated a "hold (c)" rating on shares of Hims & Hers Health in a research note on Monday, December 29th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $25.00 to $28.00 and gave the stock a "hold" rating in a research note on Tuesday, March 10th. Zacks Research upgraded shares of Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research note on Wednesday, February 25th. BTIG Research downgraded shares of Hims & Hers Health from a "buy" rating to a "neutral" rating in a report on Tuesday, February 24th. Finally, Leerink Partners decreased their target price on shares of Hims & Hers Health from $20.00 to $17.50 and set a "market perform" rating on the stock in a research report on Tuesday, February 24th. Three equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $30.75.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.